Any Australian who has filled a prescription at the chemist will have been asked if they want a branded product or the generic version. And with consumers looking to cut costs wherever they can ...
As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.